According to overseas network reports, the New York Times published an article entitled “It’s Time to Trust China and Russia’s Vaccines” on the 5th local time, pointing out that Chinese and Russian vaccines have been scientifically tested to prove safe and effective and recognized by their peers.
When the global vaccine distribution is unfair and Europe is in short supply, the article calls on Western countries to trust the coronavirus vaccine developed by China and Russia to fill the gap in vaccination in various countries.
The article said that for some time, there has been a lot of evidence that the coronavirus vaccine developed by China and Russia is safe and effective.
The medical journal The Lancet published the interim results of the later trials this week in support of the Russian “satellite V” coronavirus vaccine.
After the trial in Turkey, the coronavirus vaccine developed by China’s Kexing has been officially recognized by the country.
In addition, many evidence has been peer-reviewed or published in scientific journals such as The Lancet and the Journal of the American Medical Association after independent trials of these vaccines in both countries.
Now, in the face of severe vaccine shortages and delays in delivery in EU countries, France, Spain and Germany are now talking about the possibility of ordering vaccines from China and Russia.
In the face of the predicament, they shouted that there should be no “bias” against non-Western vaccines.
The Governor of Chang’an Street (WeChat ID: Capitalnews) previously reported that the British Telegraph reported that vaccines in China and Russia are helping Latin American countries fight the coronavirus pandemic.
The inoculated person expressed his gratitude, saying that he saw “the dawn after a long night”.
The report said that across Latin America, from some world-class big cities to remote areas, the second wave of the coronavirus pandemic has lost control. And the United States, the United Kingdom and the European Union are giving priority to vaccinating the domestic population.
Latin American governments have no way to turn to it, but to improve and place their hopes on vaccine manufacturers in China and Russia.
